Cargando…

miR-142-5p regulates CD4(+) T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

The present study aimed to evaluate the function of microRNA (miR)-142-5p on cancer immunity to induce apoptosis in human non-small cell lung cancer (NSCLC) and its mechanism. miR-142-5p expression was upregulated, and CD4(+) T cell levels were reduced in patients with NSCLC. Overexpression of miR-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Jun, Ling, Xiean, Peng, Bin, Ding, Guanggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059749/
https://www.ncbi.nlm.nih.gov/pubmed/29767245
http://dx.doi.org/10.3892/or.2018.6439
Descripción
Sumario:The present study aimed to evaluate the function of microRNA (miR)-142-5p on cancer immunity to induce apoptosis in human non-small cell lung cancer (NSCLC) and its mechanism. miR-142-5p expression was upregulated, and CD4(+) T cell levels were reduced in patients with NSCLC. Overexpression of miR-142-5p expression inhibited the cancer effects of CD4(+) T cells on NSCLC cell lines, and downregulation of miR-142-5p increased the cancer effects of CD4(+) T cells on NSCLC cell lines, compared with the control group. In addition, we found that overexpression of miR-142-5p suppressed PTEN protein expression and induced PI3K, p-Akt and PD-L1 protein expression in an in vitro model of NSCLC. Downregulation of miR-142-5p induced PTEN and PD-L1 protein expression and suppressed PI3K and p-Akt and protein expression in an in vitro model of NSCLC. The suppression of PD-L1 reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. The inhibition of PTEN also reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4(+) T cells in human NSCLC through PD-L1 expression via the PTEN pathway.